Skip to main content

HYPOTHESIS AND THEORY article

Front. Mol. Med
Sec. Molecular Medicine and Cancer Treatment
Volume 4 - 2024 | doi: 10.3389/fmmed.2024.1461151

DeltaRex-G, Tumor Targeted Retrovector Encoding a CCNG1 Inhibitor for CAR-T Cell Therapy Induced Cytokine Release Syndrome

Provisionally accepted
Grace Haroun Grace Haroun 1Erlinda M. Gordon Erlinda M. Gordon 2*
  • 1 University of California, Los Angeles, Los Angeles, California, United States
  • 2 Cancer Center of Southern California, Santa Monica, United States

The final, formatted version of the article will be published soon.

    Cytokine release syndrome is a serious complication of chimeric antigen receptor-T cell therapy and is triggered by excessive secretion of inflammatory cytokines by chimeric T cells which could be fatal. Following an inquiry into the molecular mechanisms orchestrating cytokine release syndrome, we hypothesize that DeltaRex-G, a tumor targeted retrovector encoding a cytocidal CCNG1inhibitor gene, may be a viable treatment option for corticosteroid-resistant cytokine release syndrome. DeltaRex-G received United States Food and Drug Administration Emergency Use Authorization to treat Covid-19-induced acute respiratory distress syndrome, which is due to hyperactivated immune cells. A brief administration of DeltaRex-G would inhibit a certain proportion of hyperactive chimeric T cells, consequently reducing cytokine release while retaining chimeric T cell efficacy.

    Keywords: DeltaRex-G, CAR-T cell therapy, cytokine release syndrome, COVID-19, Acute respiratory disease

    Received: 07 Jul 2024; Accepted: 06 Sep 2024.

    Copyright: © 2024 Haroun and Gordon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Erlinda M. Gordon, Cancer Center of Southern California, Santa Monica, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.